Clinical Trials Logo

Clinical Trial Summary

This trial studies the natural history of brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery. Learning about brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery may help doctors learn more about the disease and find better methods of treatment and on-going care.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine if there is difference in the average changes of neurocognitive function (NCF) scores from baseline to the time of radiologic tumor progression or up to 5 years (whichever occurs first), between radiologically progressed and non-progressed patients.

SECONDARY OBJECTIVES:

I. To determine if there is difference in the time to neurocognitive decline, as defined by the Reliable Change Index - Within subjects Standard Deviation (RCI-WSD), between radiologically progressed and non-progressed patients.

II. To evaluate NCF during the postoperative observational period of progression-free survival (PFS) and after radiological progression for a total time on study of 5 years.

III. To determine if the changes in cognitive functioning are an early warning biomarker for radiological progression.

IV. To explore the effect of salvage therapy on cognitive outcomes in patients who progress during the study period for up to 5 years.

V. To evaluate quality-of-life (QOL) as measured by the European Organization for Research and Treatment of Cancer (EORTC) QOL-30 and QOL brain module (BCN20) and health utilities as measured by the European Quality of Life-5 Dimensions (EQ-5D), for a total time on study of 5 years.

VI. To evaluate seizure control for a total time on study of 5 years. VII. To evaluate molecular correlates of QOL, NCF, seizure control, and PFS. VIII. To characterize aberrant molecular pathways in low-grade gliomas (LGGs) and test the hypothesis that activation of signaling pathways will predict worse PFS and overall survival (OS).

IX. To explore the relationship between change in cognitive function and symptomatic progression (defined as worsening seizures or new or progressive neurologic deficits) or clinical progression (defined as initiation of treatment interventions such as radiotherapy, chemotherapy, or additional surgery).

OUTLINE:

Patients undergo neurocognitive assessment using the CogState Test battery (the Detection Test (DET), the Identification Test (IDN), the One Card Learning Test (OCLT), and the Groton Maze Learning Test (GMLT)) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC Quality of Life Questionnaire-Core 30 (QOL-30), the Brain Cancer Module-20 (BCM20), and the European Quality of Life-5 Dimensions (EQ-5D) questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.

Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure.

NOTE: * 12 weeks after surgery. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01417507
Study type Observational
Source Radiation Therapy Oncology Group
Contact
Status Completed
Phase N/A
Start date October 2011
Completion date December 2014

See also
  Status Clinical Trial Phase
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Completed NCT00830635 - Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer N/A
Completed NCT00951626 - A Standardized Nursing Intervention Protocol for HCT Patients N/A
Completed NCT00466830 - Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer N/A
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Withdrawn NCT00397501 - BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain Phase 1/Phase 2
Completed NCT01217424 - Reflexology or Aromatherapy Massage in Relieving Symptoms in Patients With Cancer N/A
Completed NCT00956475 - Quality of Life in Younger Leukemia and Lymphoma Survivors Phase 1
Withdrawn NCT00873600 - Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer N/A
Completed NCT00932997 - Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors N/A
Completed NCT00400699 - Radiation Therapy Outreach Program for Minority or Low-Income Patients With Newly Diagnosed Cancer N/A
Completed NCT00410579 - Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers N/A
Completed NCT00363909 - Citalopram in Treating Postmenopausal Women With Hot Flashes Phase 3
Completed NCT00915889 - Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors N/A
Completed NCT00713505 - Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction N/A
Withdrawn NCT00770419 - Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers N/A
Recruiting NCT00503646 - Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners N/A
Completed NCT00755313 - Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer N/A
Completed NCT00372840 - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer N/A
Completed NCT00085176 - Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia N/A